Updated:
KYNTRA BIO
Kyntra Bio, founded by Daniel Lee, builds clinical-trial workflow software that automates study startup and site management for biotech companies.
KYNTRA BIO
Kyntra Bio emerged from the recognition that clinical trials remain the pharmaceutical industry's most expensive bottleneck, consistently delayed by fragmented data systems and labor-intensive monitoring. The company builds cloud-based software that unifies trial design, site selection, patient recruitment, and regulatory documentation into a single platform. Its approach targets the middle market of biotech firms that lack the internal infrastructure of large pharmaceutical companies but must still meet the same FDA requirements. The platform's core value proposition is compressing trial timelines by automating the coordination between sites, sponsors, and regulators. The firm sells its platform on a subscription basis, positioning itself as the operational backbone for clinical-stage biotech companies. Kyntra's technology ingest protocols from trial designs and dynamically generates workflows for site activation, patient enrollment tracking, and adverse event reporting. It competes with legacy electronic data capture systems and the traditional full-service CRO model by promising biotech companies they can retain more control over trial execution while reducing monitoring costs. The platform's real-time dashboards aim to replace the weekly PDF reports that still dominate trial management communication. Kyntra Bio was founded by Daniel Y. Lee, who serves as the firm's public-facing executive. The company operates from the United States and has maintained a lean structure consistent with an early-stage vertical SaaS company. It has not publicly disclosed external fundraising rounds or revenue figures, suggesting it may be bootstrapped or funded by a small group of early backers. Kyntra's known footprint is concentrated in the U.S. market, though its cloud-native architecture makes geographic expansion plausible without requiring physical site presence. What structurally separates Kyntra from both traditional CROs and general-purpose life-science software vendors is its singular focus on trial execution as a workflow problem rather than a staffing or data-capture problem. Traditional CROs sell labor and expertise; Kyntra sells a tool that allows biotech firms to manage their own trials with fewer external hires. This creates a clean delineation: Kyntra does not conduct trials — it gives companies the system to run them internally. That architectural choice makes it a horizontal threat to the mid-tier CRO market rather than a competitor to any one services firm.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Principals
Daniel Y. Lee
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at Kyntra Bio?
Kyntra Bio is an operating company, not an investment firm. Founder Daniel Y. Lee leads the company's business decisions. The firm has not disclosed a board of directors or external investment partners, so governance appears concentrated with the founder at this stage.
How does Kyntra Bio differ from a traditional contract research organization?
Kyntra Bio does not conduct clinical trials — it sells software that lets biotech companies run their own trials more efficiently. Traditional CROs like IQVIA or Parexel employ thousands of clinical research associates who monitor sites in person. Kyntra's model replaces that labor layer with workflow automation, which shifts cost and control back to the sponsor. This distinction matters: Kyntra competes with the CRO model while operating as a technology vendor, not a regulated services provider.
Does Kyntra Bio target specific therapeutic areas?
The firm has not published a therapeutic-area restriction. Its platform appears designed to be therapy-agnostic, automating operational workflows that apply across oncology, rare disease, cardiology, and other clinical domains. The restrictions that matter are trial-phase and regulatory-context constraints, not disease-specific ones.
Is Kyntra Bio subject to FDA regulation?
Kyntra Bio's software, if used to manage electronic trial master files or capture source data, likely falls under FDA 21 CFR Part 11 requirements for electronic records and signatures. However, the company itself is not regulated as a drug developer or clinical investigator. Its regulatory exposure is as a software vendor to regulated entities, which is standard for clinical technology companies.
What is Kyntra Bio's known posture on co-investments alongside external GPs?
Kyntra Bio is not an investment vehicle. It is an enterprise software company building a clinical-trial operating system. Any discussion of co-investment or fund structures does not apply. Firms analyzing Kyntra should approach it as a potential operating asset or direct investment in a healthcare-technology company, not as a GP or fund commitment.
How is Kyntra Bio funded?
Kyntra Bio has not publicly disclosed its funding structure. It may be bootstrapped, angel-backed, or funded through a small early-stage venture round. No named venture capital investors are associated with the company in public record. This opacity is common for early-stage vertical SaaS companies that have not yet raised an institutional round.
What makes Kyntra Bio's market different from general clinical-trial software?
The clinical-trial software market is fragmented between electronic data capture (EDC), clinical trial management systems (CTMS), and site-selection tools. Kyntra Bio's pitch appears to be unification — replacing the patchwork of point solutions and manual CRO coordination with a single platform. This horizontal-integration thesis is a different structural bet from the best-of-breed approach common in life-science IT budgets.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: